Christopher J. Morl
Keine laufenden Positionen mehr
Profil
Christopher J.
Morl formerly worked at Alethia Biotherapeutics, Inc., as Director from 2010 to 2016, Ambit Biosciences Corp., as Chief Operations Officer from 2010 to 2012, miRagen Therapeutics, Inc., as Chief Operating Officer in 2016, GSK Plc, as General Manager from 1998 to 2001, Agensys, Inc., as Vice President-Business Development, KINOMEscan, as Chief Business Officer, and Deciphera Pharmaceuticals, Inc., as Chief Business Officer from 2016 to 2020.
Mr. Morl received his undergraduate degree from the University of London and Masters Business Admin degree from Cranfield School of Management.
Ehemalige bekannte Positionen von Christopher J. Morl
| Unternehmen | Position | Ende |
|---|---|---|
| DECIPHERA PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01.07.2020 |
Alethia Biotherapeutics, Inc.
 Alethia Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Alethia Biotherapeutics, Inc. discovers and develops therapeutic mAbs against highly-disease tissue specific novel clinically-relevant targets. The firm focuses on bone loss in acute disorders, invasive carcinomas and on cancer-associated epithelial-to-mesenchymal transition. The company was founded in 2002 by Mario Filion and Yves Cornellier and is headquartered in Montreal, Canada. | Direktor/Vorstandsmitglied | 01.12.2016 |
miRagen Therapeutics, Inc. /Old/
 miRagen Therapeutics, Inc. /Old/ Pharmaceuticals: MajorHealth Technology miRagen Therapeutics, Inc. develops microRNA-based therapeutics for cardiovascular and muscle diseases. It leverages in-house expertise in miRNA biology, oligonucleotide chemistry, and drug development to evaluate and advance RNA-based technologies and potential drug candidates for its own pipeline and in strategic collaborations. The firm aso focuses on hematological malignancies, fibrosis and neuro inflammation. The company was founded by William S. Marshall, Michael R. Bristow, Marvin H. Caruthers, Bruce Lee Booth and Eric Newell Olson in 2007 and is headquartered in Boulder, CO. | Geschäftsführer | 14.06.2016 |
| AMBIT BIOSCIENCES CORP | Geschäftsführer | 01.02.2012 |
| GSK PLC | Corporate Officer/Principal | 01.01.2001 |
Ausbildung von Christopher J. Morl
| University of London | Undergraduate Degree |
| Cranfield School of Management | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| GSK PLC | Health Technology |
| DECIPHERA PHARMACEUTICALS, INC. | Health Technology |
| Private Unternehmen | 5 |
|---|---|
Ambit Biosciences Corp.
 Ambit Biosciences Corp. Pharmaceuticals: MajorHealth Technology Ambit Biosciences Corp. develops pharmaceutical drugs. It engages in discovery, development and commercialization of small-molecule kinase inhibitors for the treatment of cancer. The firm provides drug to treat unmet medical needs in oncology, autoimmune and inflammatory diseases. The company was founded on May 17, 2000 and is headquartered in San Diego, CA. | Health Technology |
miRagen Therapeutics, Inc. /Old/
miRagen Therapeutics, Inc. /Old/ Pharmaceuticals: MajorHealth Technology miRagen Therapeutics, Inc. develops microRNA-based therapeutics for cardiovascular and muscle diseases. It leverages in-house expertise in miRNA biology, oligonucleotide chemistry, and drug development to evaluate and advance RNA-based technologies and potential drug candidates for its own pipeline and in strategic collaborations. The firm aso focuses on hematological malignancies, fibrosis and neuro inflammation. The company was founded by William S. Marshall, Michael R. Bristow, Marvin H. Caruthers, Bruce Lee Booth and Eric Newell Olson in 2007 and is headquartered in Boulder, CO. | Health Technology |
Agensys, Inc.
 Agensys, Inc. Miscellaneous Commercial ServicesCommercial Services Agensys, Inc. develops a pipeline of therapeutic fully human monoclonal atibodies (mAbs) to treat cancer. It develops a pipeline of naked and antibody-drug conjugated (ADC) therapeutic antibodies to treat cancer indications, including prostate, kidney, pancreas, ovary, bladder, lung, colon, breast, and skin. The company was founded in 1997 and is headquartered in Santa Monica, CA. | Commercial Services |
Alethia Biotherapeutics, Inc.
Alethia Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Alethia Biotherapeutics, Inc. discovers and develops therapeutic mAbs against highly-disease tissue specific novel clinically-relevant targets. The firm focuses on bone loss in acute disorders, invasive carcinomas and on cancer-associated epithelial-to-mesenchymal transition. The company was founded in 2002 by Mario Filion and Yves Cornellier and is headquartered in Montreal, Canada. | Health Technology |
KINOMEscan
 KINOMEscan Miscellaneous Commercial ServicesCommercial Services KINOMEscan provides kinase screening services. The company is headquartered in San Diego, CA. | Commercial Services |
